• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

    2/10/23 2:27:32 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials
    Get the next $IGNY alert in real time by email
    SC 13G/A 1 e618267_sc13ga-ignyte.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 2) *

     

    Peak Bio, Inc. (formerly known as Ignyte Acquisition Corp.)

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    70470P108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

     

    ----------

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

    CUSIP No. 70470P108 13G Page 2 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    362,500 (1)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    362,500 (1)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    362,500 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.78%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

    __________________

    (1) Comprised of shares of common stock underlying an equal number of warrants held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

      

    CUSIP No. 70470P108 13G Page 3 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    362,500 (2)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    362,500 (2)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    362,500 (2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.78%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

    __________________

    (2) Comprised of shares of common stock underlying an equal number of warrants held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

      

    CUSIP No. 70470P108 13G Page 4 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    362,500

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    362,500

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    362,500

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.78%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

     

    CUSIP No. 70470P108 13G Page 5 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    362,500 (3)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    362,500 (3)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    362,500 (3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.78%

    12.

    TYPE OF REPORTING PERSON*

     

    IN

    __________________

    (3) Comprised of shares of common stock underlying an equal number of warrants held by Deerfield Partners, L.P.

      

    CUSIP No. 70470P108 13G Page 6 of 9

     

    Item 1(a). Name of Issuer:
       
     

    Peak Bio, Inc.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    3350 W. Bayshore Rd., Suite 100

    Palo Alto, CA 94303

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock

       
    Item 2(e). CUSIP Number:
       
     

    70470P108

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

         
    (g) ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

         

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

         
    (i) ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    CUSIP No. 70470P108 13G Page 7 of 9

     

         
    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. - 362,500 shares

    Deerfield Management Company, L.P. - 362,500 shares

    Deerfield Partners, L.P. - 362,500 shares

    James E. Flynn – 362,500 shares

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 1.78%

    Deerfield Management Company, L.P. – 1.78%

    Deerfield Partners, L.P. – 1.78%

    James E. Flynn – 1.78%

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 362,500

    Deerfield Management Company, L.P. - 362,500

    Deerfield Partners, L.P. - 362,500

    James E. Flynn – 362,500

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 362,500

    Deerfield Management Company, L.P. - 362,500

    Deerfield Partners, L.P. - 362,500

    James E. Flynn – 362,500

      

    **See footnotes on cover pages which are incorporated by reference herein.

     

    CUSIP No. 70470P108 13G Page 8 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☒.

       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

     

    CUSIP No. 70470P108 13G Page 9 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DEERFIELD MGMT, L.P. 

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: February 10, 2023

     

     

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.

     

    Exhibit B. Item 8 Statement.

     

    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

     

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Ignyte Acquisition Corp. shall be filed on behalf of the undersigned.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner 

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

     

    Get the next $IGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGNY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    SEC Filings

    View All

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    2/6/24 4:09:01 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/29/24 5:08:05 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/3/24 5:08:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

    Combined Company Scheduled to Commence Trading on NASDAQ Under the Ticker Symbol "PKBO" Peak Bio Co., Ltd. ("Peak Bio"), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the "Business Combination") with Ignyte Acquisition Corp. (NASDAQ:IGNY) ("Ignyte"), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte's stockholders held on October 25, 2022 (the "Special Meeting"). Ignyte's stockholders also voted to approve all other proposals presented at the Special Meeting. Ignyte's Board of Direct

    11/2/22 7:30:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

    Transaction Expected to Close on October 31, 2022 Ignyte Acquisition Corp. ("Ignyte") (NASDAQ:IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte's stockholders have approved its proposed business combination (the "Business Combination") with Peak Bio Co., Ltd. ("Peak Bio") at a Special Meeting of its stockholders held on October 25, 2022 (the "Special Meeting"). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Special Meeting, representing approximately 75% of Ignyte's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approv

    10/27/22 8:05:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Financials

    Live finance-specific insights

    View All

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Ignyte Acquisition Corp.

    SC 13D - Peak Bio, Inc. (0001834645) (Subject)

    3/21/23 5:30:30 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Ignyte Acquisition Corp.

    SC 13G - Peak Bio, Inc. (0001834645) (Subject)

    2/28/23 4:01:06 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

    SC 13G/A - Peak Bio, Inc. (0001834645) (Subject)

    2/14/23 3:39:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials